Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Wells Fargo & Company
Investment analysts at Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Friday, MarketBeat reports. The brokerage set an “overweight” rating and a $115.00 price target on the biotechnology company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of […]
Investment analysts at Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Friday, MarketBeat reports. The brokerage set an “overweight” rating and a $115.00 price target on the biotechnology company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of […]
